|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
TXC treatment reversed cartilage degeneration related biomarkers (ADAMTS 4, ADAMTS 5, Col I, Col V, MMP 3, MMP 9, and MMP 13) and inflammation factors (IL-1β, TNF-α, and IL-6) in both the animal and cellular OA models.
|
31760158 |
2020 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
This study revealed that the cartilage protective effect of osthole in a MIA-induced osteoarthritis (OA) murine model can be explained by downregulation of COX-2 and RUNX2 by inhibition of NF-κB and HIF-2α up-regulated by OA induction, resulting in downregulation of MMP-13, Syndecan IV and ADAMTS-5.
|
31765607 |
2020 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our experiment in vivo found that the degeneration of condylar cartilage caused by unilateral anterior crossbite (UAC) model, characterized by obvious degenerative morphology, loss of cartilage extracellular matrix, up-regulation of TNF-α, HIF2α and its' down-stream OA-related cytokines (MMP-13, VEGF and Col X), could be alleviated by lack of oestrogen while aggravated by high level of oestrogen in rats.
|
31678498 |
2020 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
In vivo experiments using surgically-induced OA rats showed <sub>MC</sub> SOX9/6/shANG-tADSC-treated rats had significantly lower levels of cyclooxygenase (COX-2) and MMP13 in synovial fluids than <sub>MC</sub> SOX9/6-tADSC-treated rats, but no significant difference was observed between them in histological appearances.
|
30957437 |
2020 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Previous studies using the controlling abnormal joint movement (CAJM) model of OA reported delayed cartilage degeneration; however, none of them focused on gait performance and the localization of matrix metalloproteinase 13 (MMP13) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in chondrocytes.
|
29938527 |
2020 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Notably, the Pearson coefficient demonstrated that the levels of the RAS components were positively correlated with the expression of VEGF and MMP-13 in OA and RA.
|
31785770 |
2020 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The most recent studies have suggested a role for the TGF-Beta, HtrA1, Ddr2, and Mmp-13 pathway in the degradation of articular cartilage and the development of OA in cho/+ mice.
|
30719872 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The expression of OA associated biomarkers namely Matrix metalloproteinase (MMP-13), NOD-, LRR- and pyrin domain-containing 3 (NLRP3) induced by destabilizing the medial meniscus operation (DMM) were also investigated.
|
31407595 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
These insights may serve as a potential starting point of further experimental validation and structure-based drug design/repurposing of MMP-13 inhibitors for the treatment of OA.
|
31378153 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The acquisition of a hypertrophic phenotype (producing aberrant type X collagen and catabolic MMP-13 protease) by chondrocytes is well documented and contributes to OA development.
|
30853397 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The gene expression of matrix metalloproteinase (MMP)1, MMP3, MMP13, interleukin (IL)-1β, IL-6 and tumor necrosis factor-α were reduced in the cartilage of OA mice following 7,8-DHF treatment.
|
31410125 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Matrix metalloproteinase-13 (MMP-13) is an attractive drug target for the treatment of osteoarthritis (OA).
|
30774858 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Functionally, intra-articular treatment with IL-36Ra attenuated OA development in mice, and IL-36RN reduced MMP13 in human OA chondrocytes.
|
31068441 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Even in the absence of injury, osteocytic MMP13 deficiency was sufficient to reduce cartilage proteoglycan content, change chondrocyte production of collagen II, aggrecan, and MMP13, and increase the incidence of cartilage lesions, consistent with early OA.
|
31700695 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Using an in vivo rabbit model of OA, we asked, does an intra-articular injection of chloramphenicol in the knee (4) induce autophagy; (5) reduce OA severity; and (6) reduce MMP-13 expression?
|
31764352 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Mechanistic study showed that circRNA.33186 directly binds to and inhibits miR-127-5p, thereby increasing MMP-13 expression, and contributes to OA pathogenesis.
|
30692016 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to investigate the role of Notch signaling changes during proliferation and differentiation of chondrocyte, and to testify the mechanism of MMP-13 regulation by Notch and Runx2 expression changes during osteoarthritis.
|
31666602 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Circ_0136474 could suppress cell proliferation by facilitating MMP-13 expression and suppressing miR-127-5p expression in OA.
|
31402547 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
In addition, OA chondrocytes produced higher amount of [type 2 collagen (COL-2) and glycosaminoglycan (GAG)], as well as lower level of matrix metalloproteinase 13 (MMP-13) in KGN thermogel that those in thermogel with no addition of KGN.
|
31681730 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
In conclusion, MSCs-CM demonstrated satisfactory effect in alleviating OA in rats via protecting the microarchitecture of subchondral bone, balancing the ratio of MMP-13 to TIMP-1 in cartilage, and enhancing autophagy, which might provide a new remedy against OA.
|
31210406 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the present study suggests that XIST promotes MMP‑13 and ADAMTS5 expression, indicating ECM degradation, by functioning as a ceRNA of miR‑1277‑5p in OA.
|
31198977 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Design, cyclization, and optimization of MMP13-TIMP1 interaction-derived self-inhibitory peptides against chondrocyte senescence in osteoarthritis.
|
30352228 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
One month following MLI, the numbers of MMP13-positive and TUNEL-positive chondrocytes were significantly greater in the articular cartilage of the RUNX2 OE joints compared to control joints and 2 months following MLI, histomorphometry and Osteoarthritis Research Society International (OARSI) scoring revealed decreased cartilage area in the RUNX2 OE joints.
|
31189030 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of MMP-13 and ADAMTS-5 in 5-AzadC-treated OA chondrocytes was prevented by miR-140-5p inhibitor transfection.
|
31077718 |
2019 |
|
Degenerative polyarthritis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Mechanistically, Arg-II appears to cause OA cartilage destruction at least partly by upregulating the expression of matrix-degrading enzymes (matrix metalloproteinase 3 [MMP3] and MMP13) in chondrocytes via the nuclear factor (NF)-κB pathway.
|
30610061 |
2019 |